PROVENTION BIO, INC.

(PRVB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Provention Bio Shares Rise 13% After Plan to Resubmit BLA

01/28/2022 | 10:23am EDT

By Chris Wack


Provention Bio Inc. shares were up 13% to $3.85 Friday after the company said it intends to resubmit the teplizumab biologics license application for the delay of clinical type 1 diabetes in at-risk individuals following its Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration.

The company said the purpose of the Type B pre-BLA resubmission meeting was to discuss FDA feedback and obtain agreement on Provention's proposed clinical pharmacology data package.

In preliminary meeting comments, the FDA noted that the data package presented doesn't adequately support pharmacokinetic comparability because predicted primary PK parameters are indicative of a lower exposure.

To address this concern, the FDA proposed, and the company agreed, to use PK modeling to adjust the 14-day dosing regimen for the planned commercial product to match the exposure of clinical material used in prior clinical trials by ensuring that the 90% confidence intervals for relevant PK parameters fall within the target 80% to 125% range. On this basis, the FDA agreed that Provention could proceed to resubmit the BLA.

Under applicable FDA guidelines, the FDA has 30 days to review the BLA resubmission, determine whether it is complete and acceptable for review, and provide the due date for action. Under BTD and priority review designation, the FDA's guidance is to complete its review within six months of the BLA resubmission date.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-28-22 1023ET

All news about PROVENTION BIO, INC.
05/12Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential C..
PR
05/05TRANSCRIPT : Provention Bio, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05PROVENTION BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/05Provention Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/05Earnings Flash (PRVB) PROVENTION BIO Reports Q1 Loss $-0.35, vs. Street Est of $-0.47
MT
05/05Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Updat..
PR
05/03Provention Bio Announces the Grant of Inducement Awards
PR
04/28Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
PR
04/04Provention Bio Announces the Grant of Inducement Awards
PR
03/28Provention Bio's PRV-101 Meets Primary Endpoint in Phase 1 Study
MT
More news
Analyst Recommendations on PROVENTION BIO, INC.
More recommendations
Financials (USD)
Sales 2022 8,47 M - -
Net income 2022 -165 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,81x
Yield 2022 -
Capitalization 264 M 264 M -
Capi. / Sales 2022 31,2x
Capi. / Sales 2023 2,70x
Nbr of Employees 82
Free-Float 82,8%
Chart PROVENTION BIO, INC.
Duration : Period :
Provention Bio, Inc. Technical Analysis Chart | PRVB | US74374N1028 | MarketScreener
Technical analysis trends PROVENTION BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,13 $
Average target price 16,21 $
Spread / Average Target 293%
EPS Revisions
Managers and Directors
Ashleigh W. Palmer Chief Executive Officer & Director
Thierry Chauche Chief Financial Officer
Wayne F. Pisano Chairman
Francisco Leon Chief Scientific Officer
Eleanor Leni Ramos Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROVENTION BIO, INC.-27.58%264
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601